conference "The best in Asco Emirates 2025" Discuss the developments of diagnosis and treatment of tumors

Abu Dhabi on June 22 / WAM / The “Best of the UAE 2025” conference, organized by the “Pure Health” group “Sahi”, discussed in cooperation with Tawam Hospital, and with the participation of a group of the most prominent oncology experts from all over the world, the latest developments in the diagnosis and treatment of tumors, and the exchange of experiences and knowledge about the latest scientific and technical innovations in this field.

In its third edition, the conference sessions, for two days, witnessed specialized scientific shows, which focused on the latest developments in multiple areas of oncology, including breast cancer, digestive system cancers, and women’s tumors. The conference, which concluded today, dealt with the developments of immunotherapy, directed treatment and modern techniques in early monitoring and diagnosis.

Professor Debo Tebathi, from the University of Texas and head of the Breast Oncology Department at the MD Anderson Cancer Center in the United States of America, said in a statement to “WAM”, that the session in which he shed light on the results of his research, as he discussed in his scientific presentation the issue of targeting estrogen receptors, as one of the central paths responsible for the development and continuation of breast cancer.

He added that the current stage is witnessing the emergence of new treatments that constitute a qualitative shift in this field, as they are not limited to modern hormonal treatments, but also include targeted biological treatments such as “CDK” inhibitors and “PI3” inhibitors, which caused a qualitative shift in the treatment of the disease.

He pointed out that these treatments contribute to improving the results of the treatment of advanced breast cancer, as the most prominent treatments being tested in this framework were discussed during the conference, and with their effectiveness in the advanced stages of the disease, and their use is currently expanded in the early stages and auxiliary treatment.

And Professor Debo Trebathi presented during his participation expanded information about the effectiveness of “CDK” inhibitors in the early stages, stressing that it contributes to reducing relapse, with the possibility of their future impact in reducing death rates, although the time is still early for the final judgment on this effect, but he expressed optimism about the future of these treatments.

He explained that the data for the drug “Ribociclib” appears to be particularly promising, in addition to the availability of encouraging results about the drug “Abemaciclib”, considering that the adoption of these drugs may make a tangible difference in the path of patient treatment.

Tebathti touched on the remarkable progress in the field of cellular DNA released from “CTDNA” tumors, explaining that following molecular changes in the blood may allow the possibility of proactive treatment before the emergence of clinical progress of the disease, a field that is rapidly evolved and represents a major axis of discussion during this conference.

He stressed the importance of holding this conference as a global platform that brings together a group of experts, especially from the Middle East, where the region records high rates of patients in the younger age groups, which requires the development of treatment strategies specially designed to meet their needs.

For his part, Dr. Faisal Al-Turkit, Consultant of Oncology and Head of the Breast Cancer Unit at the Kuwait Center for Cancer Control, indicated in his statement to a recent study discussed at the conference “Best of what is in Asco Emirates 2025”, the possibility of reducing the doses of traditional chemotherapy in the “Her2-Positive” breast cancer doses, explaining that The study confirmed that patients in the first and second stages can dispense with giving “carbplatine”, which leads to a significant reduction in complications without affecting the effectiveness of treatment.

He pointed out that this study represents a qualitative shift in modifying therapeutic protocols, and improving the quality of patients ’life, stressing that the application of its results will have a tangible positive impact during its follow -up to patients in Kuwait.

He stressed the importance of continuing participation in scientific conferences because of its role in enhancing cooperation and exchanging experiences between the Gulf states and the UAE, especially in light of the unique challenges facing the region, including the small age of patients with breast cancer compared to Western countries, where the average age of patients with risk in America and Europe is about 64 years, while the Gulf states record injuries at the ages of less than 40 years.

He stressed the need to intensify early detection programs, especially for age groups less than 40 years, stressing that early detection raises healing rates to more than 90% when the disease is discovered in its early stages, as well as the risks of postponing the examination and detection, stressing that the delay in the diagnosis leads to the exacerbation of the disease and is difficult to treat it, calling for the necessity of early detection as a decisive step in combating breast cancer.

• For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter